Viracta is committed to advancing new medicines based on its viral activation therapy approach to benefit patients with viral-associated cancers and other serious diseases. Viracta’s proprietary platform is a highly targeted combination therapy approach for virus-associated malignancies. The Company's initial focus is on cancers associated with the Epstein Barr Virus. Viracta will also expand into additional applications to utilize this approach to benefit patients with a range of virus-associated diseases.